That seems to be for Hepatitis C, not AGVHD so why the comparison. What are the other cures for AGVHD to compare with? For the FDA proof we have to wait for the publication of the phase III results.
The pricing of any cell therapies will only be what the market will bear by comparison to the other options, a life time of medication or other outcomes.
Cell Therapy News/Articles, page-34
-
- There are more pages in this discussion • 18,406 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.54 | $1.48 | $5.605M | 3.713M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 55197 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 29782 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |